TMEM59L and neoplasm: TMEM59L also showed a negative correlation with tumor mutational burden (TMB) in many cancers, such as HNSC, LUAD, LIHC, KIRC, BRCA, THCA, BLCA, KIRP, LGG, ESCA, PAAD, UCEC, and STAD and a negative correlation with microsatellite instability (MSI) in UCEC, ACC, ESCA, LAML, and STAD, which suggest that TMEM59L may reflect cancer immunogenicity in these cancer types (Figures 6D–E and Table S3).